Oxipurinol - XORTX Pharma

Drug Profile

Oxipurinol - XORTX Pharma

Alternative Names: Oxypurinol - XORTX; XORLO; XRx-008

Latest Information Update: 15 Feb 2016

Price : $50

At a glance

  • Originator XORTX Pharma
  • Class Anti-ischaemics; Antigouts; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Xanthine oxidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Autosomal dominant polycystic kidney disease

Most Recent Events

  • 15 Feb 2016 Clinical trials in Autosomal-dominant polycystic kidney disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top